Načítá se...
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
We report the effectiveness of daratumumab, a human IgGκ monoclonal antibody targeting CD38 on plasma cells, for therapy-refractory antibody-mediated rejection (AMR) due to blood group antibodies in a 59-year-old man who received a living ABO-incompatible kidney transplantation. Standard treatment o...
Uloženo v:
| Vydáno v: | Case Rep Nephrol Dial |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
S. Karger AG
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6902247/ https://ncbi.nlm.nih.gov/pubmed/31828078 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503951 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|